• Good results in tests for BioNeutral's anti-anthrax technology

    New Jersey company uses its Ygiene formulation to kill anthrax spores on contact; formulation killed all anthrax spores exposed to the formulation in as little fifteen seconds

  • New bird flu vaccine looks promising

    Baxter’s cell-based vaccine appears to work better than more traditional egg-based ones; tests show promise at low doses

  • India to test anthrax vaccine

    India is worried about bioterror attacks by Islamic extremists; it starts testing the potency of U.S.-manufactured vaccine; initially enough doses will be stored to protect military personnel

  • Investing in biodefense companies

    Billions of dollars are pouring into biodefense vaccines and treatments; do companies engaged in developing such vaccines and treatment offer attractive investment opportunities? The answer is a qualified “Yes” to this specific question — but a more resounding “Yes” when these companies’ other research and development endeavors are taken into consideration

  • Florida stocks cyanide antidote

    Minute quantities of cyanide in smoke contribute to the death from smoke inhalation of 10,000 civilian and firefighter in the United States each year; Florida emergency services decide that emergency units will now be equipped with cyanide antidote

  • Market for molecular diagnostic technologies to grow

    The last few years have seen major strides forward in molecular diagnostic technologies; new report asses size of markets and opportunities in it

  • Insecticides in pet shampoo may trigger autism

    New study shows that children growing up in a household in which pet shampoos containing a class of insecticide called pyrethrins were used, were twice as likely to develop autism spectrum disorder (ASD)

  • Human testing of Vietnamese-made H5N1 vaccine

    Vietnam begins human testing of Vietnamese-made H5N1 vaccine; initial tests involve 240 volunteers; Vietnam has already tested avian flu vaccine on monkeys and reports results were encouraging

  • Pandemic flu may be well mitigated until vaccine is available

    New study shows that high levels of compliance, ascertainment, and social distancing would make it possible to mitigate a flu pandemic until a vaccine is available

  • Avalanche of drugs, scarcely any oversight, I

    More and more drugs are imported by U.S. drug makers from China, then re-labeled and sold in the United States; even when the drugs are made in the United States, more and U.S. drug makers purchase the drug ingredients in China; trouble is, the FDA does not have the resources to inspect these Chinese manufacturers to see whether they adhere to U.S. safety standards; the result: U.S. consumers become ill and die

  • Worrying about wrong threat weakens U.S. bioterrorism preparedness

    Science writer says that the worry about man-made pathogens (or “designer” pathogens) is misplaced; preoccupation with artificial germs has led the government to de-emphasize “one-bug-one-drug” strategy in favor of “broad spectrum technology” aiming to boost the body’s innate, or general, immunity; experts question wisdom of strategy

  • Infectious diseases on the rise around the world

    Researchers offer proof that there is distinct, measurable rise in infectious diseases around the world; most of these diseases, including SARS and the Ebola virus, originated in wildlife; antibiotic drug resistance has been cited as another culprit, leading to diseases such as extremely drug-resistant tuberculosis (XDR TB)

  • CDC says influenza B strain does not match vaccine

    The U.S. flu season started out slowly, but activity has increased sharply, which is typically the case; the bad news is that most circulating influenza B viruses tested so far this season do not match this year’s vaccine, signaling that two of the three vaccine components are off-target

  • New vaccine against deadliest strain of avian flu tested by scientists

    University of Pittsburgh researchers test new H5N1 vaccine; unlike other avian flu vaccines, which are partially developed from live viruses, the new vaccine uses a virus-like particle which is recognized by the immune system as a real virus but lacks genetic information to reproduce, making it a potentially safer alternative for a human vaccine